Med. Oncol.

Increased lanosterol turnover: a metabolic burden for daunorubicin-resistant leukemia cells.

Stäubert C, Krakowsky R, Bhuiyan H, ..., Broom O, Nordström A

Med. Oncol. 33 (1) 6 [2016-01-00; online 2015-12-23]

Affiliated researcher

Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.

Sooman L, Lennartsson J, Gullbo J, ..., Blomquist E, Ekman S

Med. Oncol. 30 (3) 638 [2013-06-20; online 2013-06-20]

Affiliated researcher

Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.

Suzuki C, Blomqvist L, Hatschek T, ..., Jacobsson H, Glimelius B

Med. Oncol. 30 (1) 415 [2013-03-00; online 2013-01-16]

Affiliated researcher